While there may still be a place for direct CB1R agonists for the treatment of conditions such as chronic neuropathic pain and multiple sclerosis, the potential risk these may carry for exacerbating psychiatric conditions, particularly psychosis and schizophrenia and possibly bipolar disorder, will likely limit their utility for the treatment of psychiatric conditions. Here, CNR1 is linked to schizophrenia.